A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia

Phase 1 Completed 12 enrolled NCIC Clinical Trials Group S*BIO · collab

NaSingle-groupOpen-labelTreatment

Summary

This research is being done because SB939 has been shown to shrink tumours in animals and in some people and seems promising, but we are not sure if it can offer better results than standard treatment.

Timeline

Start: 2010-10-01
Primary completion: 2012-04-12
Completion: 2014-01-16

Publications

Results Zorzi AP, Bernstein M, Samson Y, Wall DA, Desai S, Nicksy D, Wainman N, Eisenhauer E, Baruchel S. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium. Pediatr Blood Cancer. 2013 Nov;60(11):1868-74. doi: 10.1002/pbc.24694. Epub 2013 Jul 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pracinostat	Other / unclassified	20 mg/m2	Oral
Subject	Pracinostat	Other / unclassified	25 mg/m2	Oral
Subject	Pracinostat	Other / unclassified	35 mg/m2	Oral
Subject	Pracinostat	Other / unclassified	45 mg/m2	Oral

A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia

Summary

Timeline

Publications

Drugs

Indications